{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:06:17Z","timestamp":1783933577586,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":71,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020357","name":"Amneal Pharmaceuticals LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100435","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:56:28Z","timestamp":1773942988000},"page":"100435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Opicapone in Parkinson\u2019s patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study"],"prefix":"10.1016","volume":"14","author":[{"given":"Olga","family":"Klepitskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"LeWitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Kilbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Seeberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn T.","family":"Stebbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Serbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena C.","family":"Brigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Rattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.prdoa.2026.100435_b0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40120-022-00435-8","article-title":"Off-time treatment options for Parkinson's disease","volume":"12","author":"Fabbri","year":"2023","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100435_b0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41531-023-00589-8","article-title":"Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson's disease - network meta-analysis","volume":"9","author":"Sako","year":"2023","journal-title":"NPJ Parkinsons. Dis."},{"issue":"11","key":"10.1016\/j.prdoa.2026.100435_b0015","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.29193","article-title":"Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson's disease","volume":"37","author":"Ferreira","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2026.100435_b0020","article-title":"The cost-effectiveness of opicapone versus entacapone as adjuvant therapy for levodopa-treated individuals with Parkinson's disease experiencing end-of-dose motor fluctuations","volume":"2025","author":"Harrison-Jones","year":"2025","journal-title":"Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.prdoa.2026.100435_b0025","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/ene.15990","article-title":"Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment","volume":"30","author":"Harrison-Jones","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.prdoa.2026.100435_b0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial","volume":"15","author":"Ferreira","year":"2016","journal-title":"The Lancet Neurology"},{"issue":"2","key":"10.1016\/j.prdoa.2026.100435_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","article-title":"Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Lees","year":"2017","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100435_b0040","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/mds.28507","article-title":"Non-motor fluctuations in Parkinson's disease: validation of the non-motor fluctuation assessment questionnaire","volume":"36","author":"Kleiner","year":"2021","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100435_b0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson's disease severity levels and MDS-unified parkinson's disease rating scale","volume":"21","author":"Mart\u00ednez-Mart\u00edn","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2026.100435_b0050","unstructured":"F.a.D.A. (FDA), Ongentys\u00aehighlights of prescribing information, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212489s000lbl.pdf. 2024)."},{"issue":"4","key":"10.1016\/j.prdoa.2026.100435_b0055","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/biom11040612","article-title":"Treatment options for motor and non-motor symptoms of Parkinson\u2019s disease","volume":"11","author":"Church","year":"2021","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.prdoa.2026.100435_b0060","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/mds.28507","article-title":"Non-motor fluctuations in Parkinson\u2019s disease: validation of the non-motor fluctuation assessment questionnaire","volume":"36","author":"Kleiner","year":"2021","journal-title":"Movement Diorders"},{"issue":"1","key":"10.1016\/j.prdoa.2026.100435_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40035-020-00187-1","article-title":"Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study","volume":"9","author":"Reichmann","year":"2020","journal-title":"Translational Neurodegeneration"},{"issue":"9","key":"10.1016\/j.prdoa.2026.100435_b0070","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/14737175.2021.1968298","article-title":"Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert Rev. Neurother."},{"issue":"6","key":"10.1016\/j.prdoa.2026.100435_b0075","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","article-title":"Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations","volume":"130","author":"Regensburger","year":"2023","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.prdoa.2026.100435_b0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CIA.S3787","article-title":"Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease","volume":"4","author":"Truong","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.prdoa.2026.100435_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.754016","article-title":"The added benefit of opicapone when used early in parkinson's disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and -II","volume":"12","author":"Rocha","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2026.100435_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.994114","article-title":"The safety\/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and II","volume":"13","author":"Rocha","year":"2022","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.prdoa.2026.100435_b0095","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1007\/s00415-024-12614-8","article-title":"Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies","volume":"271","author":"Ferreira","year":"2024","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.prdoa.2026.100435_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci15050532","article-title":"Real-world use of COMT inhibitors in the management of patients with Parkinson's disease in Spain who present early motor fluctuations: interim results from the REONPARK study","volume":"15","author":"L\u00f3pez-Manzanares","year":"2025","journal-title":"Brain Sci."},{"key":"10.1016\/j.prdoa.2026.100435_b0105","article-title":"Opicapone in Parkinson's disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit","author":"Pellicano","year":"2025","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/j.prdoa.2026.100435_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00702-023-02700-y","article-title":"A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates","volume":"131","author":"Metta","year":"2024","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.prdoa.2026.100435_b0115","unstructured":"J.J. Ferreira, M.F. Gago, R. Costa, M.M. Fonseca, J. Almeida, J.F. Rocha, J. Holenz, C. Trenkwalder, Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial, J. Parkinson\u2019s Dis. 0(0) 1877718X241306711."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100435_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12030383","article-title":"Opicapone improves global non-motor symptoms burden in Parkinson's disease: an open-label prospective study","volume":"12","author":"Santos Garc\u00eda","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.prdoa.2026.100435_b0125","article-title":"EPO-747 - Opicapone's real-world experience in Spanish patients with Parkinson's disease: The OPTIMO study, European Academy of","author":"Luquin","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2026.100435_b0130","article-title":"Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson's disease","author":"Fiores","year":"2025","journal-title":"SSRN"},{"key":"10.1016\/j.prdoa.2026.100435_b0135","article-title":"Opicapone improves motor and non-motor wearing off symptoms in Parkinson\u2019s disease: an observational real-world study [abstract]","author":"Oehlwein","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2026.100435_b0140","article-title":"Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study. [abstract]. , Movement Disorders Societ","author":"Manzanares","year":"2024","journal-title":"Mov. Disord."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:19:26Z","timestamp":1783930766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["S2590112526000150"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100435","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opicapone in Parkinson\u2019s patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100435"}}